Top Markets
Coin of the day
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Classement en actions #27865
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Prix de l'action
$1.00
Dernière synchronisation: 2023-06-01
Capitalisation boursière
$30.11M
Changement (1 jour)
2.04%
Changement (1 an)
0.00%
Pays
US
Échange Angion Biomedica Corp. (ANGN)

Catégorie

Ratio P/B pour Angion Biomedica Corp. (ANGN)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Angion Biomedica Corp., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Angion Biomedica Corp. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH